WeLeader Biomedical Co., Ltd. (TPEX:7713)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Premium Product	166.38M	155.57M	165.55M	102.42M
Premium Product Growth	6.95%	-6.03%	61.64%	-
Adjustments and Write-Offs	-267.00K	-904.00K	-3.23M	-3.85M
The Company	825.01M	786.04M	873.39M	742.56M
The Company Growth	4.96%	-10.00%	17.62%	-
Total	991.13M	940.70M	1.04B	841.14M
Total Growth	5.36%	-9.17%	23.13%	-

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Taiwan	991.13M	940.70M	1.04B	841.14M
Taiwan Growth	5.36%	-9.17%	23.13%	-
Total	991.13M	940.70M	1.04B	841.14M
Total Growth	5.36%	-9.17%	23.13%	-

Source: S&P Global Market Intelligence.